Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.63 |
| ▸ | IKBKB | O14920 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | FRK | P42685 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.55 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.55 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790306 | 0.92 | MAPK14 (0.61) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5790800 | 0.91 | MAPK14 (0.60) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5793520 | 0.88 | MAPK14 (0.71) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5205132 | 0.86 | MAPK14 (0.62) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5808419 | 0.85 | MAPK14 (0.54) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5805532 | 0.85 | MAPK14 (0.54) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5805528 | 0.85 | MAPK14 (0.54) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL6508068 | 0.84 | MAPK14 (0.53) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL4258909 | 0.80 | MAPK14 (0.59) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5790672 | 0.80 | MAPK14 (0.69) | MAPK14IKBKBMAPK13PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | claimed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | claimed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | claimed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | claimed |
| US-7067527-B2 | Thienopyridine derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-27 | — | — | US | disclosed |
| WO-2006006691-A2 | SOLID DISPERSION OF A P38 MAP KINASE INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-19 | — | — | WO | disclosed |
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1259515-B1 | THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040054183-A1 | Thienopyridine derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-6653476-B2 | Antiinflammatory and antiarthritic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-25 | — | — | US | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-20030130517-A1 | Thienopyridine derivatives , their production and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1259515-A2 | THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001064685-A2 | THIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | MAPK14 50/4885IKBKB 119/4885MAPK13 72/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | MAPK14 29/4885IKBKB 25/4885MAPK13 50/4885 |
| US-20030130517-A1 | Thienopyridine derivatives , their production and use | ALK, HRH2, TBXA2R | MAPK14 2965/4885IKBKB 321/4885MAPK13 3327/4885 |
| US-20040054183-A1 | Thienopyridine derivatives, their production and use | ALK, HRH2, TBXA2R | MAPK14 2965/4885IKBKB 321/4885MAPK13 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.